Outcome of patients receiving thrombolytic therapy while on rivaroxaban for non-valvular atrial fibrillation (from ROCKET AF)
The American Journal of Cardiology Aug 17, 2017
Chen ST, et al. – Researchers performed a retrospective analysis of outcomes of all patients who received thrombolytic therapy in the ROCKET AF trial in order to assess the safety of intravenous thrombolysis in this group of patients. Findings indicated that careful assessment of time since last dose may be of clinical importance in patients on NOACs who need emergent thrombolysis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
